Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Up 8.1%

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) traded up 8.1% during trading on Thursday . The company traded as high as $2.80 and last traded at $2.80. 6,604 shares were traded during mid-day trading, a decline of 65% from the average session volume of 18,945 shares. The stock had previously closed at $2.59.

Analyst Upgrades and Downgrades

Separately, Raymond James raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, May 22nd.

Eupraxia Pharmaceuticals Stock Down 7.1 %

The firm has a market cap of $70.93 million and a P/E ratio of -2.80. The company’s 50-day moving average is $2.69.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last released its earnings results on Wednesday, May 8th. The company reported ($0.21) earnings per share for the quarter.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 13,000 shares of the company’s stock, valued at approximately $34,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.